INCYTE - Dusseldorf Stock Exchang (ICY DU) stock market data APIs
€70.1087
0.66(0.9%)
as of September 16, 2025
Try our APIs with
free plan!
INCYTE - Dusseldorf Stock Exchang Financial Data Overview
Price chart is built with
Anychart
There is no Profile data available for ICY.DU.
Prev. Close
70.1087
Open
70.7715
High
70.4762
Low
69.9426
52 wk Range
48.52-77.8
Market Cap
12 792 M
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get INCYTE - Dusseldorf Stock Exchang data using free add-ons & libraries
Get INCYTE - Dusseldorf Stock Exchang Fundamental Data
INCYTE - Dusseldorf Stock Exchang Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: NaN
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
INCYTE - Dusseldorf Stock Exchang News
New
Alger Russell Innovation Index Updates for Third Quarter 2025
NEW YORK, Sept. 15, 2025 /PRNewswire/ -- Fred Alger Management, LLC ("Alger"), a privately held growth equity investment manager, today announced the quarterly rebalancing of the Alger Russell Innovat...
Incyte Corporation (INCY) Advances KRAS Cancer Program
In this article, we will be taking a look at the 11 Best Performing Biotech Stocks So Far in 2025. Incyte Corporation is one of them. Incyte Corporation (NASDAQ:INCY), a global biopharmaceutical com...
Incyte to Present New Data Highlighting Progress Across its Dermatology Pipeline at the European Association of Dermatology and Venerology 2025 Congress
- 24-week data from the Phase 3 STOP-HS clinical trial program of povorcitinib in patients with hidradenitis suppurativa (HS) selected as a late-breaking oral presentation WILMINGTON, Del., September...
Biotech Sector Shows No Signs of Slowing. 3 Stocks That Make the Grade.
Biotech stocks are on a winning streak that might just continue through the rest of the year. When the biotech sector shows signs of renewed strength, it often signals a broader risk-on sentiment amon...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
